Shares of OncoSec Medical Incorporated (NASDAQ:ONCS) were up 10.1% on Wednesday . The company traded as high as $1.09 and last traded at $1.09. Approximately 647,330 shares changed hands during mid-day trading, an increase of 568% from the average daily volume of 96,977 shares. The stock had previously closed at $0.99.

A number of analysts have recently weighed in on ONCS shares. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of OncoSec Medical in a research note on Friday, June 2nd. Maxim Group restated a “buy” rating and issued a $5.00 target price on shares of OncoSec Medical in a research note on Thursday, May 18th. Noble Financial reiterated a “buy” rating on shares of OncoSec Medical in a report on Friday, May 12th. Dawson James reiterated a “buy” rating and issued a $5.00 price target on shares of OncoSec Medical in a report on Thursday, July 6th. Finally, ValuEngine upgraded OncoSec Medical from a “strong sell” rating to a “sell” rating in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $5.33.

The stock’s market cap is $23.07 million. The stock’s 50-day moving average is $0.99 and its 200-day moving average is $1.13.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/09/06/oncosec-medical-incorporated-oncs-trading-up-10-1.html.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.